- Demonstrate an increase in the learner’s knowledge of clinical medicine.
- Demonstrate an improvement in the learner’s ability to make decisions that provide safe and effective medical care.
- Recognize areas of personal strength and areas for growth in clinical knowledge.
Physicians and residents who are seeking to maintain and augment their knowledge in clinical medicine and/or preparing for their initial board certification or recertification.
The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities.
All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.
AMA Credit Designation Statement
The Massachusetts Medical Society designates this enduring material for a maximum of 357 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 357 hours of Category 1 credit for completing this program.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 357 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College of Physicians and Surgeons of Canada
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Method of Participation
You must answer questions correctly to receive CME credit and MOC points.
Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™.
Six questions answered correctly equal 1 MOC point.
CME credit and MOC points are available for 3 years. Term begins January 27, 2020.
Original Release Date: January 27, 2014
Review dates: 2015, 2016, 2017, 2019, 2020, 2021, 2022
Termination Date: January 27, 2024
MMS Disclosure PolicyThe Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities. All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.
Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.
Vaneeta Bamba, MD
|2021||Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020|
Ethan Brown, MD
|2021||Rune Labs, consultant, discontinued Apr 2019|
|2022||Rune Labs, consultant|
Steven Chen, MD
|2022||Pfizer, advisory board member, discontinued May 2021|
Novartis, advisory board member, discontinued Dec 2021
Ezra M. Cohen, MD
|2021||Cornerstone Research Group, consultant|
|2023||Presidio, scientific board member|
Nathan Connell, MD
|2022||Takeda Pharmaceutical, consultant|
|2023||Takeda Pharmaceutical, consultant|
Genentech, advisory board member
Areeg H. El-Gharbawy, MD
|2021||Ultragenyx, principal investigator for a clinical trial|
Ultragenyx, advisory board member
Amicus, advisory board member
Rajesh T. Gandhi, MD
|2021||Merck, scientific advisory board|
Glenn J. Hanna, MD
Actuate Therapeutics, grant/funding
Bicara, consultant/advisory board
Boxer Capital, consultant
Bristol Myers Squibb, grant/funding
Bristol Myers Squibb, consultant
Elevar, consultant/advisory board
Exicure, grant/funding, discontinued Jan 2022
Exicure, consultant/advisory board
Gateway for Cancer Research, grant/funding
General Catalyst, consultant
Kartos Therapeutics, grant/funding
Kite Pharma, grant/funding, discontinued Jun 2022
KSQ Therapeutics, consultant
KSQ Therapeutics, grant/funding
Kura Oncology, consultant/advisory board
Kura Oncology, grant/funding
Merck, consultant/advisory board
Naveris, consultant/advisory board
Prelude, consultant/advisory board
Rain Therapeutics, consultant, discontinued Nov 2021
Regeneron, consultant/advisory board
Remix Therapeutics, consultant/advisory board
Sanofi Genzyme, advisory board, discontinued Nov 2021
Sanofi Genzyme, grant/funding
Secura Bio, grant/funding
V Foundation, grant/funding, discontinued Jun 2022
Jonathan S. Hausmann, MD
Pfizer, consultant, discontinued Dec 2020
Biogen, consultant, discontinued Dec 2020
Pfizer, consultant, discontinued Dec 2020
Biogen, consultant, discontinued Dec 2020
|2023||Fresenius Kabi, consultant|
Brian C. Healy, MD
Analysis Group, grant support
Analysis Group, research support to institution, discontinued Nov 2020
Novartis, research support
Koyal Jain, MD, MPH
PI for Kaneka study and Visterra study
Mihir M. Kamdar, MD
|2021||Amorsa Therapeutics, scientific advisory board, stockholder|
Medtronic, consultant, fees
Fern Health, consultant, fees
|2023||Elevate, cofounder and chief medical officer|
Fern Health, medical advisor
Ruslan Korets, MD
|2021||Boston Scientific, consultant|
|2022||Boston Scientific, consultant|
|2023||Boston Scientific, consultant|
Lekha M. Rao, MD
|2023||Epigenyx Therapeutics, consultant|
UCB, principal investigator for a clinical trial
Eisai, principal investigator for a clinical trial
Leigh C. Reardon, MD
|2022||Janssen, advisory committee|
Eric Roeland, MD
|2023||Napo Pharmaceuticals, scientific advisory board|
Actimed Therapeutics, scientific advisory board
Meter Health, scientific advisory board
Veloxis Pharmaceuticals, consultant
Aileron Therapeutics, consultant
Takeda, advisory board
Enzychem Lifesciences Pharmaceutical Company, data safety monitoring board
Deborah R. Stein, MD
Taher S. Valika, MD
|2021||Save My Scope Inc, chief medical officer|
Ruth Ann Vleugels, MD, MPH, MBA
|2021||Pfizer, principal investigator for a clinical trial|
Raymond Y. Wang, MD
Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019
Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019
RegenxBio, advisory committee, discontinued May 2020
Takeda Pharmaceutical, advisory committee, discontinued Aug 2020
Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020
Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020
Neurogene, advisory committee, discontinued Nov 2020
Denali Therapeutics, drug monitoring committee
Biomarin, ad hoc advisory board, discontinued Oct 2021
Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021
Sio Gene Therapies, consultant, discontinued Nov 2021
Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021
Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021
Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021
Ultragenyx, speaker, discontinued Nov 2020
Neurogene, ad hoc advisory board, discontinued Oct 2020
Regenxbio, ad hoc advisory board, discontinued Apr 2020
Takeda Pharmaceutical, advisory committee, discontinued 2022
Denali, drug safety monitoring board
Sharmeel K. Wasan, MD
|2021||Pfizer, grant support|
All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.
Disclosure of Commercial Support
No commercial support was received for this activity.
Medium or Combination of Media Used
This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.
Estimated Time to Complete the Educational Activity
One hour for every 6 questions answered correctly.
Each clinical vignette includes citations and references.
Policy on Privacy and Confidentiality
Participant data is governed by ABIM’s Confidentiality Policy and submitted to the ABIM using the ACCME PARS system. Identifiable patient data shall not be provided to ACCME or ABIM by any organization or participant.
Public Information About Providers of MOC Activities
The following information, provided to ACCME by the provider, is considered public information, and therefore may be released by ABIM and/or ACCME.
- Activity title
- Activity type
- Accredited provider name
- Accredited provider contact information (including phone number and website address)
- Joint provider name (if applicable)
- Activity date (start date, in the case of a multi-day live activity or enduring material activity)
- Specialty(ies) activity addresses
- Maximum allowable MOC points and patient safety credit awarded
The following information will be made available in physicians’ MOC history reports located in the secure physician login area of ABIM’s website:
- Activity title
- MOC point value, including patient safety credit, if applicable
- Activity completion date